Scholar Rock Holding Corp. Stock

$32.65

1.89%

Nasdaq, Aug 29, 11:55 pm CET

ISIN

US80706P1030

Symbol

SRRK

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Scholar Rock Holding Corp. Stock price

$32.65

+17.55 116.23% 5Y

Nasdaq, Closing price Fri, Aug 29 2025

-0.63 1.89%

ISIN

US80706P1030

Symbol

SRRK

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$3.1b

Enterprise Value

$2.9b

Net debt

positive

Cash

$295.0m

Shares outstanding

96.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | 778.4

EV/Sales

- | 717.6

EV/FCF

negative

P/B

13.5

Financial Health

Equity Ratio

77.6%

Return on Equity

-66.8%

ROCE

-111.7%

ROIC

Debt/Equity

0.2

Financials (TTM | estimate)

Revenue

$0.0 | $4.0m

EBITDA

$-321.7m | $-315.2m

EBIT

$-323.3m | $-315.9m

Net Income

$-315.7m | $-314.6m

Free Cash Flow

$-258.1m

EPS

$-2.8

FCF per Share

$-2.7

Short interest

28.2%

Employees

128

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

Scholar Rock Holding Corp. Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Scholar Rock Holding Corp. forecast:

15x Buy

94%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Scholar Rock Holding Corp. forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Scholar Rock Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	113 113	92% 92% -
- Research and Development Expense	210 210	39% 39% -
EBITDA	-322 -322	55% 55% -
- Depreciation and Amortization	1.65 1.65	33% 33% -
EBIT (Operating Income) EBIT	-323 -323	54% 54% -
Net Profit	-316 -316	55% 55% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Scholar Rock Holding Corp. Stock News

Neutral

Business Wire

●

17 days ago

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 426,250 shares of...

Neutral

Business Wire

●

18 days ago

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, announced today that positive study results from the pivotal Phase 3 SAPPHIRE trial (NCT05156320) were published in the pee...

Neutral

Seeking Alpha

●

26 days ago

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Akshay K. Vaishnaw - President of R&D, Member of Scientific Advisory Board and Director David L.

More Scholar Rock Holding Corp. News

Company Profile

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Head office	United States
CEO	David Hallal
Employees	128
Founded	2012
Website	scholarrock.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now